Omeros (NASDAQ:OMER) CAO Sells $17,304.60 in Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 906 shares of Omeros stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $19.10, for a total transaction of $17,304.60. Following the transaction, the chief accounting officer owned 5,906 shares of the company’s stock, valued at $112,804.60. The trade was a 13.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Price Performance

Shares of Omeros stock opened at $19.25 on Friday. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of 15.04 and a beta of 2.54. The firm’s 50-day moving average is $12.48 and its 200 day moving average is $11.98. Omeros Corporation has a 1 year low of $3.94 and a 1 year high of $19.65.

Omeros (NASDAQ:OMER) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million. On average, equities analysts expect that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Institutional Investors Weigh In On Omeros

Several hedge funds and other institutional investors have recently modified their holdings of OMER. UBS Group AG increased its position in Omeros by 213.5% in the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after buying an additional 1,513,893 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Omeros by 85.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company’s stock valued at $1,897,000 after buying an additional 82,646 shares in the last quarter. Corient Private Wealth LLC grew its stake in shares of Omeros by 13.0% during the 4th quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock valued at $11,817,000 after acquiring an additional 79,263 shares during the period. Compass Financial Management LLC purchased a new stake in Omeros in the 2nd quarter worth approximately $312,000. Finally, Quantinno Capital Management LP raised its stake in Omeros by 145.4% during the 1st quarter. Quantinno Capital Management LP now owns 61,541 shares of the biopharmaceutical company’s stock worth $650,000 after acquiring an additional 36,467 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OMER has been the subject of several research reports. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a report on Monday, July 27th. Finally, Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $38.00.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.